ADA urges companies to issue data on incretin treatments

06/17/2013 | MedPage Today (free registration)

The American Diabetes Association has called on manufacturers of incretin therapies to disclose all patient-level data on their products for an independent analysis that would help determine if such treatments play a role in pancreatic cancer. AstraZeneca and Bristol-Myers Squibb expressed support for the ADA's call, noting in a joint statement that they look forward to a discussion with the group about its proposal.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ